Given recent findings demonstrating that a systemically administered STING agonist leads to DC and T cell activation in spleens and tumor-draining lymph nodes (TDLNs), which may contribute to anti-tumor immunity45, we next asked whether systemic administration of a STING agonist could potentiate anti-tumor immunity and synergize with PARPi. This evidence concerns the gene STING1 and neoplasm.